Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896111 | 0.88 | NPSR1 (0.41) | PTGDR2KCNN4DRD2DRD4MEN1 | |
| SCHEMBL4899362 | 0.88 | MEN1 (0.42) | PTGDR2MEN1KMT2ACYP3A4 | |
| SCHEMBL4895747 | 0.83 | BRD4 (0.41) | PTGDR2KCNN4MEN1KMT2AENPP2 | |
| SCHEMBL4899852 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL4891152 | 0.80 | PARK7 (0.36) | MEN1KMT2A | |
| SCHEMBL4894380 | 0.79 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL4897077 | 0.76 | RIPK1 (0.38) | MEN1KMT2A | |
| SCHEMBL4897407 | 0.76 | CYP1A2 (0.39) | MEN1KMT2ACYP3A4 | |
| SCHEMBL4892448 | 0.74 | SCN9A (0.38) | PTGDR2HCRTR1HCRTR2EDNRBEDNRA | |
| SCHEMBL4887310 | 0.69 | ADRA2A (0.37) | MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | PTGDR2 2658/4885KCNN4 642/4885DRD2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.